AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2017

May 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-05-27

Reporting Person: Scadden David (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-27	Stock option (right to buy)	$48.20	A	16000	Acquired	2027-05-26	Common stock (16000)	Direct

Footnotes

F1: This option was granted on May 27, 2017. The shares underlying this option vest as to 25% of the underlying shares on May 27, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.